Biotechnology company IONTAS has announced a panel of human antibodies that neutralise elements of black mamba snake toxin in an in vivo model.
Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).
Thermo Fisher Scientific will utilise BenchSci's machine learning platform to mine antibody data published in peer-reviewed scientific journals.
A new type of medical examination glove has been developed with built-in antimicrobial technology that is proven to prevent the spread of infection.
Point of Care Diagnostics' new website, pocdscientific.com.au, enables hospitals, laboratories and researchers to order critical equipment, chemicals and pathology supplies more easily.
Microbiologics has added Escherichia coli ATCC 8739 to its EZ-Accu Shot product. This is in addition to five other USP compendial strains for growth promotion testing.
The Native Antigen Company is an expert in the production of bacterial and viral antigens, specialising in the development and manufacture of native and recombinant viral and bacterial antigens.
Bio-Rad Laboratories has launched a range of anti-idiotypic antibodies targeting the immune checkpoint inhibitor drugs pembrolizumab (Keytruda) and nivolumab (Opdivo). Anti-pembrolizumab and anti-nivolumab antibodies are designed for use in bioanalytical assays to monitor the drug levels in cancer patients.
Bio-Rad's anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanised IgG1 kappa antibody drug vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.
Bio-Rad Laboratories has announced the StarBright Blue 520 Fluorescent Secondary Antibodies — fluorescent dye-labelled secondary antibodies for use in multiplex western blotting.
Fresche Bioscience has signed an agreement to support manufacture of Stayzon's range of antimicrobial coatings and ancillary treatments.
Made from tiny nanorods, the newly developed 'NanoZymes' use visible light to create highly reactive oxygen species that rapidly break down and kill bacteria.
Nupherin, from Enzo Life Sciences, is a peptide-based transfection reagent that combines a non-classical nuclear localisation sequence (M9) with a nucleotide binding domain, thereby helping to transport DNA into the transfected cell's nucleus.